Erythermalgia: molecular basis for an inherited pain syndrome.
about
Temperature dependence of erythromelalgia mutation L858F in sodium channel Nav1.7A single sodium channel mutation produces hyper- or hypoexcitability in different types of neuronsPain as a channelopathyPrimary erythromelalgia: a reviewThe perception and endogenous modulation of painNeurobiology: a channel sets the gain on painNew concepts of neural regulation in human nasal mucosa.Pathogenic mechanisms of idiopathic nonallergic rhinitisFunctional expression, purification and high sequence coverage mass spectrometric characterization of human excitatory amino acid transporter EAAT2Pain perception is altered by a nucleotide polymorphism in SCN9ATargeting voltage sensors in sodium channels with spider toxins.A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia.Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating.A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockersMutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders.Ion channel pharmacology.Arthritis and pain. Future targets to control osteoarthritis painInhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide.Sodium channel Nav1.7 in vascular myocytes, endothelium, and innervating axons in human skin.The Biophysical Basis Underlying Gating Changes in the p.V1316A Mutant Nav1.7 Channel and the Molecular Pathogenesis of Inherited Erythromelalgia.Post-translational modifications of voltage-gated sodium channels in chronic pain syndromesConotoxins targeting neuronal voltage-gated sodium channel subtypes: potential analgesics?Mutation I136V alters electrophysiological properties of the Na(v)1.7 channel in a family with onset of erythromelalgia in the second decadeEfficacy of Anti-NaV1.7 Antibody on the Sensory Nervous System in a Rat Model of Lumbar Intervertebral Disc Injury.Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythermalgiaChannel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype.Na(+) channel blockers for the treatment of pain: context is everything, almost.Molecular and cellular limits to somatosensory specificity.Nature and nurture of human pain.Erythromelalgia in the pediatric patient: role of computed-tomography-guided lumbar sympathetic blockade.Evaluation of behavior and expression of NaV1.7 in dorsal root ganglia after sciatic nerve compression and application of nucleus pulposus in rats.Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations.Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes.Results of computer-assisted sensory evaluation in 41 patients with erythromelalgia.Sodium channels, the electrogenisome and the electrogenistat: lessons and questions from the clinic.Advances in targeting voltage-gated sodium channels with small molecules.Mutational consequences of aberrant ion channels in neurological disorders.Genotype phenotype associations across the voltage-gated sodium channel family.Spider venomics: implications for drug discovery.Genetics of chronic post-surgical pain: a crucial step toward personal pain medicine.
P2860
Q21203947-C65CE1BB-66DA-4DA7-BF35-8100D8A7BA8DQ24546007-65762BBA-3CFB-4CE6-A143-43D5B575AF17Q24622323-32DD1466-C615-4B8B-B616-CD76DE38B475Q26784432-62A914DF-88BC-47CA-94BC-1528C206FF3FQ27011310-B10A99FA-E8A2-4A9A-B175-B2A3BA6F291FQ28278802-5D997267-5E6A-4647-9D34-82AA45EBA717Q30427716-DD6DF5CF-A29D-47D5-B418-1D5786FE3CDAQ30452355-67DEDC6C-64D0-4DE4-8EA9-BD30BE3A4A70Q30981324-66954ADC-E5F1-46F0-A5D8-367D81FC150CQ33739909-7D8D32CA-8C3F-4F49-BC96-85629E5AC4BCQ33759435-CD9F146A-B38A-4C0D-8A63-72B9F55410E0Q33918510-C77975B5-9FB0-47BB-B172-2FD1CF3276C7Q34569783-FB986CA2-5F98-4476-B406-EAA26504A1DBQ34576217-E6BD1378-5893-41EB-9C4C-4250A02BB489Q34585790-B4598203-FAD5-4A5F-AC65-C3E995E55E9FQ34613758-1BD27FB6-4D4A-43C2-8A01-DDFBD2E9B5BCQ34636446-59577F61-5CC3-4DA1-A162-7E59F9A048B9Q35275248-BB8F89A2-EFD4-4794-95A9-9B35B08492A7Q35659204-4F0C8BC8-1ED2-4C7A-8ECB-6948BA738664Q36139482-0F03D904-4EC8-4EA8-849F-B9CB8771A0C4Q36249467-19265257-BA47-4213-A8ED-E98CEA728F7EQ36432810-BB6ABC55-FDC1-4F38-958F-407580E62AD8Q36487377-DCFD56A1-2497-4B13-B3BA-033EE150AB88Q36707953-1BBE3610-5376-4FF7-B247-42F32BD53EBFQ36727094-2A25559F-9CFB-481C-B74D-E68A5D3D19EAQ36771264-0CCEF45C-E381-4835-A50D-4592E0B36166Q37072034-F99572FA-A82D-468C-A8E3-45C6BFF48C8FQ37141302-0D443690-D7B2-4C50-93CE-0F4488630125Q37287580-B1F886B9-4BC9-44A6-9875-BD32829B819BQ37365507-2F13E679-EE62-4D0F-BC3F-8411DED9FA8EQ37530667-4C6F27FF-78AC-416B-BA39-4226640E14BDQ37943756-29284DEB-C5F7-4FB8-AF6B-5F639FA39AC3Q37946885-22FDA19B-597A-4144-A5FE-76B31B38551FQ37988595-84588827-2CDA-45E9-BDEC-A3FC444B4804Q37992862-77C24539-74DF-4CA7-88E0-66BAFB98FA65Q38040330-D630A178-72FE-4F7A-835E-54373C7C7A93Q38239544-6D3A67B8-59B1-4E96-813B-BAC64D0185EDQ38243946-99EF2CF9-4710-4059-BE14-2CAE6B6DC7C4Q38269167-347DE97D-BEB0-4CA1-84ED-971776CA3918Q38282574-39D094E7-D4C7-49D0-8056-36C1F89BD50A
P2860
Erythermalgia: molecular basis for an inherited pain syndrome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Erythermalgia: molecular basis for an inherited pain syndrome.
@ast
Erythermalgia: molecular basis for an inherited pain syndrome.
@en
type
label
Erythermalgia: molecular basis for an inherited pain syndrome.
@ast
Erythermalgia: molecular basis for an inherited pain syndrome.
@en
prefLabel
Erythermalgia: molecular basis for an inherited pain syndrome.
@ast
Erythermalgia: molecular basis for an inherited pain syndrome.
@en
P1476
Erythermalgia: molecular basis for an inherited pain syndrome.
@en
P2093
Stephen G Waxman
Sulayman Dib-Hajj
P304
P356
10.1016/J.MOLMED.2005.10.004
P577
2005-11-08T00:00:00Z